Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK7791 Switch Study in Hyperphosphatemia
NCT03831607Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenapanor in hyperphosphatemia, sponsored by Kyowa Kirin. Primary endpoint: Percentage of subjects who reduce the total number of taking phosphate binder tablets at Week 26. Started Dec 2018; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03831607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831607.